Strong year expected for M&A in biotech

2022 was a weak year when it came to mergers and acquisitions in the life science sector. The weak stock market performance lead to the lowest levels of deals and a lower total volume than what has been seen in many years. For 2023, however, things are looking brighter – according to analysts, transactions and volumes are expected to return to more normal levels and so far we have already seen considerable activity this year.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/01/strong-year-expected-for-ma-in-biotech/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se